MedTrace Logo

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

NCT06503848 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2024-10-28

No results posted yet for this study

Summary

The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan.

Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.

Conditions

  • Migraine Disorders

Interventions

DRUG

Sumatriptan

Register the response to treatment and headache characteristics.

Sponsors & Collaborators

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Marta Torres-Ferrús, PhD · Hospital Universitari Vall d'Hebron, Headache & Neurological Pain Research Group

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-25
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06503848 on ClinicalTrials.gov